Latest Breaking News On - நாள்பட்ட தடைசெய்யும் நுரையீரல் கோளாறு - Page 4 : comparemela.com
PAOG Announces Negotiations To Acquire Partnership Interest In Patented Cannabis Extraction Technology
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
PAOG Announces Negotiations To Acquire Partnership Interest In Patented Cannabis Extraction Technology
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
PAOG To Publish Latest CBD Pharmaceutical Developments Tomorrow, Tuesday April 13, 2021
News provided by
Share this article
Share this article
SANDUSKY, Ohio, April 12, 2021 /PRNewswire/ PAO Group, Inc. (USOTC: PAOG) today confirmed a management update on the company s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021.
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
PAO Group, Inc.: PAOG CBD Pharmaceutical Development Update Coming Tomorrow, Tuesday April 13, 2021
Sandusky, Ohio (Newsfile Corp. - April 12, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed a management update on the Company s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021.
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT .
PAOG is working with Veristat, a contract research organization (CRO), dedicated to the clinical advance of therapies and treatments through regulatory approval. PAOG anticipates soon announcing new breakthroughs in its CBD RespRx pharmaceutical research.
Share this article
Share this article
SANDUSKY, Ohio, April 8, 2021 /PRNewswire/ PAO Group, Inc. (USOTC: PAOG) today announced a management update on the company s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021.
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
PAOG is working with Veristat, a contract research organization (CRO), dedicated to the clinical advance of therapies and treatments through regulatory approval. PAOG anticipates soon announcing new breakthroughs in its CBD RespRx pharmaceutical research.
vimarsana © 2020. All Rights Reserved.